Alterity Therapeutics logo

ATH - Alterity Therapeutics Share Price

A$0.018 -0.0  -5.3%

Last Trade - 29/05/20

Sector
Healthcare
Size
Micro Cap
Market Cap £8.46m
Enterprise Value £1.90m
Revenue £30.3k
Position in Universe 1274th / 1842
Bullish
Bearish
Unlock ATH Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Financial Summary
FINANCIAL BRIEF: : For the six months ended 31 December 2019, Alterity Therapeutics Ltd revenues decreased 79% to A$14K. Net loss increased 6% to A$5.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Other income (R&D tax incentive) decrease of 24% to A$1.9M (income), Foreign Exchange Gain/Loss–Non-Business decrease of 36% to A$128K (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ATH Revenue Unlock ATH Revenue

Net Income

ATH Net Income Unlock ATH Revenue

Normalised EPS

ATH Normalised EPS Unlock ATH Revenue

PE Ratio Range

ATH PE Ratio Range Unlock ATH Revenue

Dividend Yield Range

ATH Dividend Yield Range Unlock ATH Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ATH EPS Forecasts Unlock ATH Revenue
Profile Summary

Alterity Therapeutics Limited, formerly Prana Biotechnology Limited, is a development-stage medical biotechnology company. The Company is engaged in the research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's disease, Huntington disease, Parkinson's disease and other neurological disorders. The Company's lead product candidates are PBT2 and PBT434. The Company's lead drug candidate PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. The Company also has advanced a drug candidate for Parkinson's disease and other movement disorders (PBT434) and brain cancer (PBT519), which are in pre-clinical toxicology testing. Its other applications for its therapies include certain cancers, age-related macular degeneration, Motor Neuron disease, Creutzfeldt-Jakob disease (the human variant of Mad Cow disease), and a range of orphan neurodegenerative disorders.

Directors
Last Annual June 30th, 2019
Last Interim December 31st, 2019
Incorporated November 11, 1997
Public Since March 27, 2000
No. of Shareholders: n/a
No. of Employees: 15
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Australian Stock Exchange - SEATS
Shares in Issue 872,613,872
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ATH Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ATH
Upcoming Events for ATH
Wednesday 29th July, 2020 Estimate
Q4 2020 Alterity Therapeutics Ltd Earnings Release
Wednesday 28th October, 2020 Estimate
Q1 2021 Alterity Therapeutics Ltd Earnings Release
Frequently Asked Questions for Alterity Therapeutics
What is the Alterity Therapeutics share price?

As of 29/05/20, shares in Alterity Therapeutics are trading at A$0.018, giving the company a market capitalisation of £8.46m. This share price information is delayed by 15 minutes.

How has the Alterity Therapeutics share price performed this year?

Shares in Alterity Therapeutics are currently trading at A$0.018 and the price has moved by -48.57% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Alterity Therapeutics price has moved by -43.17% over the past year.

What are the analyst and broker recommendations for Alterity Therapeutics?

There are no analysts currently covering Alterity Therapeutics.

When will Alterity Therapeutics next release its financial results?

Alterity Therapeutics is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2020-12-31
What is the Alterity Therapeutics dividend yield?

Alterity Therapeutics does not currently pay a dividend.

Does Alterity Therapeutics pay a dividend?

Alterity Therapeutics does not currently pay a dividend.

When does Alterity Therapeutics next pay dividends?

Alterity Therapeutics does not currently pay a dividend.

How do I buy Alterity Therapeutics shares?

To buy shares in Alterity Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Alterity Therapeutics?

Shares in Alterity Therapeutics are currently trading at A$0.018, giving the company a market capitalisation of £8.46m.

Where are Alterity Therapeutics shares listed? Where are Alterity Therapeutics shares listed?

Here are the trading details for Alterity Therapeutics:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: ATH
What kind of share is Alterity Therapeutics?

Based on an overall assessment of its quality, value and momentum, Alterity Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Alterity Therapeutics share price forecast 2020?

We were not able to load any forecast data for Alterity Therapeutics.

How can I tell whether the Alterity Therapeutics share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Alterity Therapeutics. Over the past six months, the relative strength of its shares against the market has been -14.6%. At the current price of A$0.018, shares in Alterity Therapeutics are trading at -21.65% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Alterity Therapeutics PE Ratio?

We were not able to find PE ratio data for Alterity Therapeutics.

Who are the key directors of Alterity Therapeutics?

Alterity Therapeutics's management team is headed by:

Kathryn Andrews - CFO
Geoffrey Kempler - CHM
Brian Meltzer - NID
Tristan Edwards - NED
Lawrence Gozlan - NID
Phillip Hains - SEC
David Stamler - SVP
David Sinclair - NED
Peter Marks - NID
Who are the major shareholders of Alterity Therapeutics?

Here are the top five shareholders of Alterity Therapeutics based on the size of their shareholding:

Life Biosciences LLC Corporation
Percentage owned: 26.02% (269.9m shares)
Goldman Sachs Financial Markets Pty. Ltd. Corporation
Percentage owned: 2.99% (31.0m shares)
Kempler (Geoffrey Paul) Individual Investor
Percentage owned: 1.74% (18.0m shares)
Jagen Pty. Ltd. Corporation
Percentage owned: 1.5% (15.6m shares)
Baywick Pty Ltd Corporation
Percentage owned: 1.37% (14.2m shares)
Similar to ATH
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.